Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million.

On April 20, Xuanzhu Bio-B announced that preliminary results from the NG-350A Phase 1b FORTRESS study will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.

NG-350A is an oncolytic immunotherapy drug intended for the treatment of mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC). The drug was licensed by the group from Akamis Bio, Inc., a clinical-stage oncology company focused on raising the standard of care for colorectal cancer.

The Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, multicenter clinical trial designed to evaluate NG-350A in combination with chemoradiotherapy (CRT) for the treatment of adult patients with pMMR LARC. Eligible patients must have at least one risk factor for local or distant recurrence, or present with oligometastatic disease.

The ongoing study aims to assess the antitumor effects of NG-350A plus chemoradiotherapy after 12 weeks of active treatment. Its goal is to determine whether NG-350A can increase the composite response rate—defined as the proportion of patients achieving clinical complete response (cCR) or near clinical complete response (ncCR)—compared to chemoradiotherapy alone in patients with pMMR locally advanced rectal cancer.